# US 2009/0269784 A1 · Protein engineering of monoacylglycerol lipase (mgll)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0269784 A1
- Document ID: US20090269784A1
- Status: Published application
- Kind: A1
- Application number: 12/429,269
- Filed: 2009-04-24
- Published: 2009-10-29
- Earliest claimed: 2008-04-25
- Assignees: Janssen Pharmaceutica NV
- Inventors: BRUCE L. GRASBERGER; CELINE SCHALK-HIHI; DIANE M. MAGUIRE; FRANK A. LEWANDOWSKI; CYNTHIA M. MILLIGAN; RICHARD S. ALEXANDER
- Web page: https://patentgrep.com/patent/US20090269784A1

## CPC

- C12N 9/18: Carboxylic ester hydrolases {(3.1.1)}
- C12Q 1/44: involving esterase
- G01N 33/573: for enzymes or isoenzymes
- C07K 2299/00: Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A number of soluble engineered forms of MGLL that are suitable for high-throughput screening and protein crystallization, as well as a crystallized form of monoacylglycerol lipase protein (MGLL) and descriptions of the X-ray diffraction patterns are disclosed. The engineered constructs of MGLL permit the expression and purification of protein suitable for crystallography or high-throughput screening and identification of ligands, which can function as active agents to MGLL. The X-ray diffraction patterns allow the three dimensional structure of MGLL to be determined at atomic resolution so that ligand binding sites on MGLL can be identified and the interactions of ligands with MGLL amino acid residues can be modeled. Models prepared using such maps permit the design of ligands which can function as active agents which include, but are not limited to, those that function as inhibitors of MGLL.

## Claims

### Claim 1

A composition comprising a form of monoacylglycerol lipase (MGLL), or a fragment, or structural motif, or derivative thereof, wherein one or more hydrophobic residues of the cap-domain is mutated to improve solubility.

### Claim 2 (depends on 1)

A composition comprising the form of MGLL of claim 1, wherein said one or more hydrophobic residues of the cap-domain is a Leucine.

### Claim 3 (depends on 1)

A composition comprising the form of MGLL claim 1, wherein said one or more hydrophobic residues of the cap-domain is selected from the group consisting of Leucine 162, Leucine 167, Leucine 169, Leucine 171, Leucine 174, Leucine 176, and Leucine 184, wherein said amino acid numbering is based on the reference sequence for human MGLL Isoform 2 (SEQ ID NO: 1).

### Claim 4 (depends on 1)

A composition comprising the form of MGLL of claim 1, wherein said one or more hydrophobic residues of the cap-domain is mutated to Serine, Glutamine, or Arginine.

### Claim 5

A composition comprising the form of MGLL as in any of the preceding claims, further comprising a Lysine mutated to an Alanine.

### Claim 6 (depends on 1)

A composition comprising the form of MGLL of claim 1, wherein said one or more hydrophobic residues is a Lysine residue selected from the group consisting of: Lysine 36, Lysine 160, Lysine 165, Lysine 188, Lysine 206, Lysine 226, Lysine 259 and Lysine 269, wherein said amino acid numbering is based on the reference sequence for human MGLL Isoform 2 (SEQ ID NO: 1).

### Claim 7 (depends on 1)

A method of identifying an agent that binds to the form of MGLL of claim 1, comprising the steps of:
a. contacting the form of MGLL with the agent;
b. determining whether the agent binds to the form of MGLL;
c. thereby identifying an agent that binds to the form of MGLL.

### Claim 8 (depends on 7)

The method of claim 7, wherein the form of MGLL has an amino acid sequence selected from the group consisting of: SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

### Claim 9 (depends on 7)

The method of claim 7, wherein the binding is determined by measuring the thermal stability of the form of MGLL.

### Claim 10 (depends on 1)

A method of identifying an agent that inhibits the activity of the form of MGLL of claim 1, comprising the steps of:
a. contacting the form of MGLL with the agent;
b. measuring the biological activity of the form of MGLL in the presence of the agent;
c. measuring the biological activity of the form of MGLL in the absence of the agent; and,
d. comparing the biological activity measured in step (b) with the biological activity measured in step (c); thereby identifying an agent that inhibits the biological activity of the form of MGLL, when the biological activity measured in step (b) is less than the biological activity measured in step (c).

### Claim 11 (depends on 10)

The method of claim 10, wherein the form of MGLL has an amino acid sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

### Claim 12 (depends on 10)

The method of claim 10, wherein the biological activity is measured with an enzyme assay.
